| Followers | 35 |
| Posts | 2798 |
| Boards Moderated | 0 |
| Alias Born | 10/28/2013 |
Monday, February 15, 2016 9:33:03 AM
Regarding stable tumor size.
I guess I undersand Pyrrho's concern about having a partially necrotic tumor; the mechanical degradation potentially allowing healthy cancer cells to float away and become mets. But, if you are going to kill the tumor you are going to have a state of mixed live and necrotic cells at some point. There is no way to avoid that, other than surgery.
Still, I would hope that the immunotherapies are better at killing single cell and small mets than the chemotherapies. The chemotherapies often rely on the cancer being more challenged than native tissue, thermally, getting oxygen, getting rid of waste and CO2, etc, all related to crowding. Single cell castaways and early mets have no such crowding. What they do have is greater surface area to volume ratios than tumors, allowing less penetrating immune components, (such as antibodies?), better access.
I know someone with lung cancer, undergoing chemo. The chemo has all tumors in a quiet state of some sort, possibly necrotic. But they can't be too certain that the tumors are dead, because they are continuing the $100K/year chemo indefinitely. I think he gets infusions every three or 4 months. There is a huge knot on his chest where he gets the infusions.
My point being that everyone is happy with the status of his cancer as stable disease. I know him because he swims laps at the same pool where I swim laps. He is a Stanford patient.
I guess I undersand Pyrrho's concern about having a partially necrotic tumor; the mechanical degradation potentially allowing healthy cancer cells to float away and become mets. But, if you are going to kill the tumor you are going to have a state of mixed live and necrotic cells at some point. There is no way to avoid that, other than surgery.
Still, I would hope that the immunotherapies are better at killing single cell and small mets than the chemotherapies. The chemotherapies often rely on the cancer being more challenged than native tissue, thermally, getting oxygen, getting rid of waste and CO2, etc, all related to crowding. Single cell castaways and early mets have no such crowding. What they do have is greater surface area to volume ratios than tumors, allowing less penetrating immune components, (such as antibodies?), better access.
I know someone with lung cancer, undergoing chemo. The chemo has all tumors in a quiet state of some sort, possibly necrotic. But they can't be too certain that the tumors are dead, because they are continuing the $100K/year chemo indefinitely. I think he gets infusions every three or 4 months. There is a huge knot on his chest where he gets the infusions.
My point being that everyone is happy with the status of his cancer as stable disease. I know him because he swims laps at the same pool where I swim laps. He is a Stanford patient.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
